


CAN SURVIVE CANCER



LONG TERM CANCER SURVIVOR RESEARCH





“I am really impressed by the commitment of all the group and by the infrastructure you have developed. You deserve a lot of credit for it. We will prepare a comprehensive proposal on potential exploratory tests (mainly immunological, but also other molecular tests) that could be performed on Continuum samples.”

José Luis Pérez Gracia
Professor of Oncology, Clinica Universidad de Navarra



“We need the help of cancer survivors to find better ways to defeat cancer. Samples from these donors are a unique source of information that will help prevent, diagnose and treat cancer patients in the future. At Continuum, donors have the unique opportunity to be part of a community of cancer survivors, healthcare professionals and research scientists with the expertise and passion to accelerate cancer survival discoveries and develop advanced therapeutics to prolong the lives of all cancer patients.”

Deyarina Gonzalez
Professor of Molecular Medicine, Swansea University



“For the first time in history, death rates from cancer are beginning to decline. Understanding the mechanisms by which extreme cancer survivors clear their cancer has potential to end the cancer epidemic. I strongly support this effort.”

Carl June
Professor of Immunology, University of Pennsylvania



MY OWN CANCER JOURNEY

In November 2010, as an apparently fit and healthy 50 year old, I was rushed into hospital and given little chance of survival. A large malignant tumour was removed from my bowel. The adjacent lymph nodes were also cancerous and I was prescribed months of intense intravenous and oral chemotherapy, most of which were developed decades ago.

14 months later (2012) a routine scan revealed a tumour in the neck of my pancreas, which, when biopsied, was confirmed as malignant; I was given 18 months to live. A complex surgical procedure was necessary to remove the tumour, which also required the removal of my spleen.

The routine scans continued and in 2013 two further tumours were discovered and subsequently removed from my liver. In 2017 a 'clinically diagnosed' malignant melanoma was removed from my scalp. Incredibly, the pathology results found no cancerous cells. In January 2018 scanning technology revealed six new tumours in my liver. A liver transplant was recommended. I refused – backing myself to recover. In May 2019 scans confirmed I had 16 tumours in my liver, these are currently stable and I feel fit and well. I am very grateful to be a cancer survivor and thankful to all those involved in my treatment.

“ I would personally like to thank you for your interest in Continuum and our landmark Long Term Cancer Survivor Study.

Our pioneering work was born out of my own experience of surviving numerous battles against multiple malignant cancers. My cancer journey has left me entirely passionate and morally obliged to discover why, and indeed how, I have survived and whether there is therapeutic potential to be learned from individual cancer survivors such as myself. I know from speaking with other cancer survivors that I am not alone in feeling like this.

Continuum has brought together some of the world's leading cancer experts and equipped them with the resources they need to carry out the research required to answer these questions. Hopefully, that potential can then be harnessed to treat cancer in a new and innovative way.

We are delighted to announce that the patent process has already commenced for some of the discoveries we have made, bringing us one step closer to finding a cure for this terrible disease.

To the many fellow cancer survivors who have already volunteered to participate in our research, I am extremely grateful. If you have yet to register, please remember your own cancer journey may well help us in our quest to find the answers we all seek. ”

James Hull

Dr James Hull, Founder and CEO



Dr Hull appears on ITV's This Morning with Professor Dan Davis, Phillip Schofield and Holly Willoughby

OUR WORK WILL BENEFIT MILLIONS WORLDWIDE

At Continuum, we are committed to finding a cure for cancer. Our innovative approach to cancer research is focussed on identifying and understanding what it is that makes some people able to survive cancer and remain cancer free. It is built on the belief that immunotherapy, which harnesses our immune system to stop cancer, is the key to the future of cancer care. Immunotherapy is already saving lives. We want to ensure it saves millions more and transforms the treatment of cancer.

The cornerstone of our work is the Continuum Long Term Survivor Study, a multidisciplinary and multi-centre study which we are undertaking in partnership with some of the world's leading medical research institutions and scientists. The key to the success of this study is seeking

out long term cancer survivors ("LTS") to participate in our study by donating blood and stools for analysis which may hold vital cancer fighting information.

Our story and news of the study have ignited massive media interest. Our extensive media activity has reached an audience of over 300 million with coverage on television and in national newspapers, in the UK and overseas.

The response from cancer survivors has been overwhelming and the number of volunteers already confirmed to participate mean it will be the largest study of its kind. By participating, you will be joining us in ground-breaking work that will make a significant difference to our knowledge of cancer and its future treatment.

Daily Mail

Is this British dentist a walking cure for cancer? How retired father-of-four, 59, has survived a string of cancers thanks to his unique blood cells which are now destroying other sufferers' cancer cells too



Could this man hold the key to future cancer treatment?:
I'm trying to find the cure for cancer says man who fended off disease four times



A man who survived different cancers four times has become the first volunteer to give blood in a study into why some people beat the disease



Continuum visit Downing Street and meet the Prime Minister and Secretary of State for Wales



The walking miracle who has survived cancer so many times he is being studied for a cure

OUR CONTINUUM RESEARCH PARTNERS

The Continuum Long Term Survivor (CLTS) Study is being conducted in partnership with six leading research institutions by teams of specialist scientists, led by the eminent Professors featured here. Whilst sharing a common goal, this is a multidisciplinary study and each team has specialist expertise and a particular area of focus in their research work. We are excited to announce further universities from the UK and the United States will be joining our unique team. This study is a truly significant initiative in the fight against cancer.



Steve Conlan
Swansea University

Research focus: Investigation of epigenomics and exosomes of the cells of the immune system.

Steve Conlan is Professor of Molecular and Cell Biology at Swansea University. He is affiliated to the Wales Cancer Research Centre.

"By understanding why some patients remain cancer free, we may be able to develop ways to treat those who do relapse. We hope that by investigating the immune system of long term cancer survivors that these secrets can be unlocked"



Dan Davis
University of Manchester

Research focus: Using 'extreme phenotypes' to define the Natural Killer cells best equipped to fight cancer: a route to new therapies.

Dan Davis is Professor of Immunology at the Manchester of University. He has published over 130 academic papers and is the author of The Beautiful Cure.

"Bringing together such a diverse group of clinicians and scientists is exciting. Breaking down barriers and engaging in interdisciplinary research gives us every chance of answering questions whose solutions are beyond the scope of a single discipline."



Lindy Durrant
University of Nottingham

Research focus: Identification of novel TCRs (T-cell receptors) and vaccine epitopes for the treatment of cancer patients from long term cancer survivors.

Lindy Durrant is Professor of Cancer Immunotherapy at the University of Nottingham. In 2019 she was awarded the Waldenstrom prize for Cancer Immunotherapy.

"We have identified some unique TCR clones from CLTS which recognise key tumour targets. There are no previous reports of T cells to these antigens, so they represent a significant step forward in immunotherapy. They also identify unique epitopes that can be used for cancer vaccines."



Kim Midwood
University of Oxford

Research focus: Exploiting anti-tumour immunity for immunotherapy in Colorectal and Pancreatic cancer.

Kim Midwood is Professor of Matrix Biology at the University of Oxford's Kennedy Institute of Rheumatology.

"We have uncovered mechanisms by which the immune response is activated early in the fight against this type of cancer, we have shown how tumours can hijack these mechanisms for their own survival, and we have also identified how CLTS can override tumour hijack such that these patients recover control over tumour growth and immune defence."



Hardev Pandha
University of Surrey

Research focus: Investigation of neoantigen molecular mimicry in long term cancer survivors.

Dr Hardev Pandha is Professor of Medical Oncology at the University of Surrey as well as Director of the Surrey Cancer Research Institute.

"The ground-breaking aspects of this project is in having access to these unique individuals and a dissection of the immune interactions in their tumour. The tumour micro-environment as a whole (rather than just the component cancer cells by themselves) dictates either the response and clearance of cancer or resistance to therapy."



Andrew Sewell
Cardiff University

Research focus: Discovering cancer specific T-Cell ligands recognised by long term cancer survivors.

Professor Sewell is Research Director of Cardiff University's Institute of Infection and Immunity.

"Thus far, we have amassed over 1,500 different cancer-killing T-cells from seven different Continuum Life Sciences extreme survivors. Over 300 of these T-cells kill multiple types of cancer."





THE CONTINUUM SUPPORT CENTRE TEAM

When you call Continuum about volunteering to participate in our Long Term Survivor Study, your first point of contact will be our helpful Support Centre. Our experienced team of nursing and operational professionals, headed up by Zoe Evans and Amy Fulcher, supported by trained volunteers, will explain the process, answer any questions and take your details. These will then be passed to our research partners who will contact you

to confirm if you are eligible to participate in the study. If you are, we will arrange an appointment for you to visit our most convenient centre to you to donate blood.

Throughout the whole process our friendly Support Centre team will be available at the end of the phone to lend their support, a sympathetic ear or answer any questions that you may have about the study and the work that we do here at Continuum.



Zoe Evans
Director of Nursing

Zoe joined Continuum Life Sciences in its very early stages. With a BSc in Clinical Practice she brings to her role as Director of Nursing an impeccable 20 year track record of nursing experience, both academic and professional.

Zoe's empathy and communication skills put people at their ease even when sharing the most intimate details of their cancer journey with us.

Zoe is the Swansea University Coordinator for Continuum donors and works closely with our Joint Clinical Research Facility there. If you have opted for Swansea as your donation centre it will be Zoe that arranges all of the logistics for the day, including travel and accommodation, liaising with the nurses on site and ensuring the blood donations are distributed safely to our other university sites. This ensures that our scientists can begin researching the cells in your blood as quickly as possible.

“ We are committed to making participating in our study as easy, enjoyable and rewarding as possible. ”



Amy Fulcher
Executive Assistant to the CEO
and Support Centre Coordinator

Amy has worked alongside Dr Hull throughout his cancer journey for almost 10 years and has been involved with Continuum Life Sciences from its inception. With an education degree and a variety of operational and industry roles to her name, she is well placed to assist in all operational areas of the organisation.

She was instrumental in setting up the Continuum Support Centre and is involved with the coordination of volunteer donors, universities and

management to ensure that things run smoothly on a day to day basis.

She is responsible for organising our quarterly symposiums where our research partners meet to discuss their research, results and next steps. As our study progresses from research to cancer therapies and vaccines Amy hopes to continue to support the team of ever-expanding universities and scientists whilst they find a cure for cancer.



MEET SOME OF OUR DONORS

Over 500 long term cancer survivors have already volunteered to participate in our study. Drawn from all walks of life and with varied medical backgrounds, our donors share a gratitude for having beaten cancer, a questioning about why they survived and a commitment to wanting to help find a cure that will help save the lives of millions of others. That's why they have chosen to get involved in our landmark study. We thought it would be helpful to share the experiences of a few of them.

TERESA SHEPPARD

“ I saw the article in the newspaper and contacted Continuum. I've survived a Whipple's Procedure for adenocarcinoma for 18 months now and wanted to see if I could participate in the study.

The Support Centre has been amazing, right from their initial response. They have been fantastic in keeping in touch with me.

I strongly encourage anyone to get in touch as the team is so helpful and will make the whole experience a pleasure as they have for me! ”

LORAIN DAWSON



“Having seen Dr James Hull on television, I felt a real connection with the fact he is a man driven for a cure after fighting the disease for so long. It takes strength, determination and a love for others to decide on a venture of this magnitude. I also think we need to look at this disease from many different new ways; cellular levels, lifestyle levels, immune systems etc. just as the Continuum study does.

“The cure could be within us. Let's target cancer together, because together we are stronger ”

You are all obviously excited and care about Continuum and its commitment to curing a disease that affects so many people's lives. To anyone thinking of calling, I would confidently say please ring.”

NICK NENADICH



“I read the article about Dr Hull and, given my cancer journey and exposure to just about all the traditional and emerging disciplines of medicine, couldn't not be interested or amazed. The part of the

“Get involved for the greater good. Your story and DNA may hold the key to new greater advances ”

story that grabbed my attention was the fact that Dr Hull was somebody who was using their experience to shape the future. It rekindles your belief in humanity. I felt compelled to call in and say, “ use my story and let me help with the fight!”



BARBARA MOSS

At the age of 52, in 2006, Barbara was diagnosed with stage IV colorectal cancer of the colon. It spread to her liver and she was told she had 3–5 months to live! Barbara is a long term survivor who today is an active campaigner and Patient Ambassador for EuropaColon and Bowel Cancer UK. We are delighted she has chosen to volunteer to participate in the Continuum Long Term Survivor Study.

“Your study starts at the finishing line and then looks at the reasons for winning. It also answers my question as to why I am alive. ”

“I felt compelled to contact Continuum as soon as I heard about Dr Hull and how he was questioning his own illness. He did not accept that you treat every cancer in the same way and he questioned why he had responded to his own treatment and survived his illness beyond expectation. I was also delighted to read that this was an independent

study that did not follow the research patterns that we are used to.

The whole Continuum team has been so kind, sensitive and supportive. The Support Centre is professional and everyone works in harmony with one another. They all have the same ambition: to help patients.

I positively encourage long term cancer survivors to contact

you and to enrol in your study. I would certainly advise anyone considering calling you to read the information on your website and to ask all the questions they would like. I have no doubt that, when they learn about this groundbreaking study, they will want to be part of it. You are just lovely people to be with and this is an exciting time! Thank you.”

Thank you to all those people who have already volunteered for the Continuum Long Term Survivor Study.

If you would like any further information or if you wish to participate we are still looking for eligible long term cancer survivors, as well as people who have had no occurrence of cancer in their family medical history.

Email: cltsstudy@continuumlifesciences.com

Freephone: +44(0)800 1 44 84 88



www.continuumlifesciences.com



@ContinuumLS



@continuumlifesciences



continuum life sciences



continuumlifesciences



Continuum Life Sciences